Chhattisgarh’s health authorities are cracking down on substandard drugs, with M/s. Effi Parenterals facing the possibility of being blacklisted. This action follows a show cause notice issued by the CGMSCL (Chhattisgarh Medical Services Corporation Limited) due to significant failures in drug quality testing.
The CGMSCL emphasizes rigorous quality control, testing all supplied drug batches before they reach health institutions. Random samples are sent to NABL-accredited labs for thorough examination, ensuring that only approved medications are distributed to patients.
Specifically, batches PGT25451, PGT25450, PGT25480, and PGT25229 of Albendazole Tablets IP 400 mg (Drug Code – D12), supplied by M/s. Effi Parenterals, were tested at the State Drug Testing and Research Laboratory, Raipur. The tests revealed that these batches did not meet the required standards. In response, and in line with its commitment to quality, CGMSCL has issued a show cause notice to the firm, with potential blacklisting. The firm is also ordered to immediately withdraw the failed batches from the warehouses.
The pharmaceutical firm had previously supplied an additional 14 batches of Albendazole Tablets IP 400 mg, which were approved for distribution after passing the necessary NABL tests.
